Remission in Adults With Mild-to-moderate Asthma in Thailand

NCT07351916 | Recruiting

• 1 other identifier: MTU-EC-IM-0-282/68
• Study Type: observational
• Target: 289
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand. The main question the study aims to answer is: What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.

Conditions

Asthma; Mild-to-moderate Asthma; Asthma Control Level

Keywords

asthma; asthma control; mild-to-moderate asthma; Thailand; remission; FeNO; blood eosinophil count

Outcome Measures

Primary Outcomes (1)

• Prevalence rate of mild-to-moderate asthma remission

  Prevalence rate of mild-to-moderate asthma remission (%)

  An average of 1 year

Secondary Outcomes (5)

• Asthma control in patients with mild-to-moderate asthma

  At baseline and at 12 months

• Airway obstruction in patients with mild-to-moderate asthma

  At baseline and at 12 months

• Severity of aiway obstruction in patients with mild-to-moderate asthma

  At baseline and at 12 months

• Eosinophil airway inflammation in patients with mild-to-moderate asthma

  At baseline and at 12 months

• Type 2 airway inflammation in patients with mild-to-moderate asthma

  At baseline and at 12 months

Study Arms (1)

Mild-to-moderate asthma

Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms \<3 times per week, have preserved lung function (FEV₁ or PEF \>80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications. Moderate asthma refers to asthma patients who have symptoms \>4-5 days per week or experience nocturnal asthma symptoms \>1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.

Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires; Other: Spirometry; Other: Fractional exhaled nitric oxide (FeNO) test; Other: Blood eosinophil count (BEC)

Interventions

Spirometry OTHER

Spirometry is a tool used to assess pulmonary function.

Mild-to-moderate asthma

Fractional exhaled nitric oxide (FeNO) test OTHER

FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.

Mild-to-moderate asthma

Blood eosinophil count (BEC) OTHER

BEC is a tool used to assess eosinophilic inflammation and asthma remission.

Mild-to-moderate asthma

Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires OTHER

GINA and ACT are questionnaires used to assess the level of asthma control.

Mild-to-moderate asthma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study

You may qualify if:

• mild-to-moderate asthma
• age 18 years or older

You may not qualify if:

• inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test

Sponsors & Collaborators

• Thammasat University: lead

Study Sites (2)

Narongkorn Saiphoklang

Pathum Thani, Changwat Pathum Thani, 12120, Thailand

RECRUITING

Faculty of Medicine, Thammasat University

Pathum Thani, 12120, Thailand

RECRUITING

Related Publications (4)

• Ishizuka M, Sugimoto N, Kobayashi K, Takeshita Y, Imoto S, Koizumi Y, Togashi Y, Tanaka Y, Nagata M, Hattori S, Uehara Y, Suzuki Y, Toyota H, Ishii S, Nagase H. Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability. J Allergy Clin Immunol Glob. 2025 Jan 30;4(2):100431. doi: 10.1016/j.jacig.2025.100431. eCollection 2025 May.

  PMID: 40091885 RESULT

• Holm M, Omenaas E, Gislason T, Svanes C, Jogi R, Norrman E, Janson C, Toren K; RHINE Study Group. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007 Jul;30(1):62-5. doi: 10.1183/09031936.00121705. Epub 2007 Mar 14.

  PMID: 17360725 RESULT

• Tupper OD, Hakansson KEJ, Ulrik CS. Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1595-1603.e5. doi: 10.1016/j.jaip.2020.11.013. Epub 2020 Nov 19.

  PMID: 33220516 RESULT

• Chiewchalermsri C, Kanjanawasee D, Saiphoklang N, Chirakalwasan N, Sriprasart T, Senavonge A, Sanguanwong N, Kamalaporn H, Athipongarporn A, Hachai S, Boonsawat W, Brannan JD, Song WJ, Ruxrungtham K, Poachanukoon O. Asthma remission: A path to cure? Asian Pac J Allergy Immunol. 2025 Jun;43(2):135-150. doi: 10.12932/AP-240525-2082.

  PMID: 40652405 RESULT

MeSH Terms

Conditions

Asthma

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Narongkorn Saiphoklang, MD

  Thammasat University Faculty of Medicine

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Narongkorn Saiphoklang, MD

CONTACT

+6629269794; M_narongkorn@hotmail.com

Sirashat Hanvivattanakul, MD

CONTACT

+6629269701; boss32_@hotmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professsor

Study Record Dates

• First Submitted: January 10, 2026
• First Posted: January 20, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): October 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: April 17, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: IPD and documents will be available for sharing immediately after publication for a period of 2 years.

Locations

TH (2)